We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+13.19%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.1B
AUM Growth
+$1.25B
Cap. Flow
-$1.53B
Cap. Flow %
-12.71%
Top 10 Hldgs %
75.84%
Holding
141
New
6
Increased
25
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$90.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$52.6M
3
DYAX
DYAX CORPORATION
DYAX
+$24.1M
4
ALKS icon
Alkermes
ALKS
+$17.5M
5
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$15.8M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$18.6M
2
XNPT
XENOPORT, INC.
XNPT
+$17M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.8M
4
RPRX
Repros Therapeutics Inc.
RPRX
+$14.5M
5
LRMR icon
Larimar Therapeutics
LRMR
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 73.26%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
101
DELISTED
Acceleron Pharma
XLRN
$1.4M 0.01%
28,765
– –
TENX icon
102
Tenax Therapeutics
TENX
$399M
$1.38M 0.01%
13
– –
PTN
103
Palatin Technologies
PTN
$14.1M
$1.36M 0.01%
1,640
– –
ADAP
104
DELISTED
Adaptimmune Therapeutics
ADAP
$1.21M 0.01%
100,000
– –
ALNY icon
105
Alnylam Pharmaceuticals
ALNY
$38.2B
$1.07M 0.01%
11,340
– –
CMRX
106
DELISTED
Chimerix, Inc.
CMRX
$1.03M 0.01%
115,216
– –
BDSI
107
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.01M 0.01%
210,021
– –
ALDX icon
108
Aldeyra Therapeutics
ALDX
$95.3M
$963K 0.01%
142,000
– –
ABUS icon
109
Arbutus Biopharma
ABUS
$849M
$804K 0.01%
180,582
– –
FPRX
110
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$799K 0.01%
19,247
– –
WINT
111
DELISTED
Windtree Therapeutics Inc
WINT
$764K 0.01%
254,975
– –
AIXC
112
AIxCrypto Holdings Inc
AIXC
$13.4M
$680K 0.01%
3
– –
AKAO
113
DELISTED
Achaogen Inc
AKAO
$574K ﹤0.01%
100,000
– –
QURE icon
114
uniQure
QURE
$2.78B
$496K ﹤0.01%
30,000
– –
FMI
115
DELISTED
Foundation Medicine, Inc.
FMI
$440K ﹤0.01%
20,892
– –
CCXI
116
DELISTED
ChemoCentryx, Inc.
CCXI
$397K ﹤0.01%
49,064
– –
LJPC
117
DELISTED
La Jolla Pharmaceutical Company
LJPC
$371K ﹤0.01%
13,746
-398,262
-97% -$10.9M
APTO
118
DELISTED
Aptose Biosciences, Inc.
APTO
$84K ﹤0.01%
74
– –
BGMSP
119
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$52K ﹤0.01%
+13,253
New +$62.2K
BTX.WS
120
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$24K ﹤0.01%
20,084
– –
LRMR icon
121
Larimar Therapeutics
LRMR
$381M
– –
-32,529
Closed -$12.5M
MTEM
122
DELISTED
Molecular Templates, Inc.
MTEM
– –
-17,730
Closed -$11.9M
CLVS
123
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-202,630
Closed -$18.6M
BLPH
124
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
– –
-23,529
Closed -$1.83M
ALDR
125
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-513,439
Closed -$16.8M
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Baker Bros. Advisors held 141 positions worth $12.1B, up 12% from $10.8B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors withdrew a net $1.53B in Q4 2015, closing 8 positions and reducing 5 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $18.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 74% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Alkermes worth $19.9M.

  • Baker Bros. Advisors's largest Q4 2015 buy was Alkermes: 250,251 shares worth $19.9M.
  • Baker Bros. Advisors added most to Acorda Therapeutics in Q4 2015, an estimated $90.4M increase.
  • Baker Bros. Advisors's biggest Q4 2015 reduction was XENOPORT, INC., cutting an estimated $17M.
  • Baker Bros. Advisors fully exited Clovis Oncology, Inc. in Q4 2015, selling an estimated $18.6M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $12.1B portfolio in Q4 2015.
  • Baker Bros. Advisors opened 6 new positions and closed 8 in Q4 2015.
  • Baker Bros. Advisors's portfolio value rose 12% quarter-over-quarter to $12.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.